Report data readouts for several investigational medicines
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 17 Dec 2019
- Due
- 31 Dec 2020
- Delivered
- by 31 Dec 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Continued pipeline progress in 2020 will include important data readouts for several investigational medicines”
What we found
Evidence strength A What the grades mean
The company reported positive data readouts for several investigational medicines, including donanemab, tirzepatide, and LOXO-305, during 2020.
-
A ELI Lilly & Co 8-K filed 2021-01-29
“I am also encouraged by exciting recent data readouts for three of our 2 most important pipeline assets: tirzepatide, LOXO-305 and donanemab.” ✓ confirmed on the page
Market reaction: the shares moved -7.0% against the S&P 500 over the three sessions around the disclosure (28 Jan 2021 to 2 Feb 2021). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- data readouts for investigational medicines
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2019-LLY-001715 · Corrections policy